Indian pharmaceutical stocks took a hit as Trump's threat of imposing tariffs on pharma imports spooked investors. Despite India's strong presence in the US generics market, potential tariffs may increase costs for US consumers and create supply chain challenges.

India reacted cautiously on Thursday to US President Donald Trump's sweeping tariffs, with the government saying it was examining both "implications" and "opportunities" from the duty hikes.